Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | GRM2 | Q14416 | 3/20 | 0.38 |
| ▸ | KMO | O15229 | 2/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.36 |
| ▸ | PGR | P06401 | 1/20 | 0.35 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.34 |
| ▸ | ESR1 | P03372 | 1/20 | 0.34 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL472426 | 0.87 | NISCH (0.39) | KMOPTGS2PTGS1ESR1ESR2 | |
| SCHEMBL472472 | 0.85 | AHR (0.45) | KMOPTGS2PTGS1CYP1A2 | |
| SCHEMBL472488 | 0.84 | PTGS2 (0.35) | PGRPTGS2PTGS1ESR1ESR2 | |
| SCHEMBL472351 | 0.82 | CYP11B2 (0.48) | GRM2 | |
| SCHEMBL472479 | 0.80 | DGAT1 (0.40) | PTGS2PTGS1 | |
| SCHEMBL472491 | 0.80 | NPC1 (0.42) | MAPK14PTGS2PTGS1 | |
| SCHEMBL9955368 | 0.77 | KDM4E (0.41) | — | |
| SCHEMBL472456 | 0.77 | GRM2 (0.41) | GRM2KMOCYP1A2 | |
| SCHEMBL472566 | 0.76 | NPC1 (0.37) | PTGS2 | |
| SCHEMBL472833 | 0.75 | KDM4E (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2412372-A1 | 2-Aminooxazole derivatives for use as TRPV1 antagonists for treating i.a. pain, inflammation, neurodegenerative diseases or gastrointestinal diseases | Abbott Laboratories (US) | 2012-02-01 | — | — | EP | disclosed |
| US-7998993-B2 | TRPV1 antagonists | ABBOTT LABORATORIES (US) | 2011-08-16 | — | — | US | disclosed |
| EP-2220059-B1 | 2-AMINOOXAZOLE DERIVATIVES AS TRPVL ANTAGONISTS USEFUL FOR TREATING PAIN | ABBOTT LAB (US) | 2011-08-03 | — | — | EP | disclosed |
| EP-2220059-A1 | 2-AMINOOXAZOLE DERIVATIVES AS TRPVL ANTAGONISTS USEFUL FOR TREATING PAIN | Abbott Laboratories (US) | 2010-08-25 | — | — | EP | disclosed |
| US-20090124666-A1 | TRPV1 ANTAGONISTS | ABBOTT LABORATORIES (US) | 2009-05-14 | — | — | US | disclosed |
| WO-2009055749-A1 | 2-AMINOOXAZOLE DERIVATIVES AS TRPVL ANTAGONISTS USEFUL FOR TREATING PAIN | ABBOTT LABORATORIES (US) | 2009-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124666-A1 | TRPV1 ANTAGONISTS | TRPV1, TRPV2, TRPV3 | ABL1 4233/4885GRM2 360/4885KMO 997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.